Comments on "anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel" [2]

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 422-423

  Fowler, Stephen ^a   Lennon, Sian M ^b   Hoffmann, Gerhard ^a   Rayner, Craig R ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CARBOXYLESTERASE; CARBOXYLIC ACID; CLOPIDOGREL; HYDROLASE; OSELTAMIVIR;

CYTOTOXICITY; DRUG ACTIVATION; DRUG BINDING; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG LIVER LEVEL; DRUG METABOLISM; HUMAN; LETTER; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; BIOTRANSFORMATION; CARBOXYLIC ESTER HYDROLASES; DRUG INTERACTIONS; HUMANS; OSELTAMIVIR; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 34250739888     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118992     Document Type: Letter

References (10)

1. He G, Massarella J, and Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37:471-484.
2. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharm Rev 50:387-411.
3. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, and Brown A (2000) The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 40:836-843.
4. Oo C, Hill G, Dorr A, Liu B, Boellner S, and Ward P (2003) Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol 59:411-415.
5. Pope CN, Karanth S, Liu J, and Yan B (2005) Comparative carboxylesterase activities in infant and adult liver and their in vitro sensitivity to chlorpyrifos oxon. Regul Toxicol Pharmacol 42:64-69.
6. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477-1484.
7. Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J (2000) Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 40:396-401.
8. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan B (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases and the hydrolyses are markedly altered with certain polymorphistic variants. J Pharmacol Exp Ther 319:1467-1476.
9. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig A, and Schomig E (2004) Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92:311-316.
10. United States Food and Drug Administration (2006) Drug Interaction Studies - Study Design, Data Analysis and Implications for Dosing and Labeling. United States Food and Drug Administration: Draft Guidance for Industry, Washington, DC.